| 产品描述： | Elacridar hydrochloride (GF120918A) is an orally active P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar hydrochloride can be used to examine the influence of efflux transporters on drug distribution to brain and it can be used for the research of cancer |
| 靶点： |
P-glycoprotein;BCRP |
| 体内研究： |
Elacridar hydrochloride (100 mg/kg; i.p. once) shows different distribution in brain and plasma |
| 参考文献： |
1. Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9. 2. Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66. |
| 溶解性： |
DMSO : 62.5 mg/mL (104.15 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.666 ml |
8.332 ml |
16.663 ml |
| 5 mM |
0.333 ml |
1.666 ml |
3.333 ml |
| 10 mM |
0.167 ml |
0.833 ml |
1.666 ml |
| 50 mM |
0.033 ml |
0.167 ml |
0.333 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京